LAX.SH
FDC LIMITED·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
340.45
+0.23%52W Range
Market Cap
₹5,542.87 Cr
Traded: ₹7.42 Cr (0.13%) 0.0x
Free Float: ₹1,254.35 Cr (0.59% of FF traded)
Volume · 60D trend
2.18 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +8.0% | +10.0% | +7.0% | -- | +3.0% | Decelerating |
| ROE | +13.0% | +12.0% | +13.0% | -- | -- | Stable |
| Return | +8.0% | +1.0% | +1.0% | -19.0% | -- | Stable |
| Profit | +6.0% | +1.0% | +16.0% | -- | +14.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 668 | 585 | 465 | 473 | 648 | 492 | 464 | 514 | 638 | 462 | 458 | 486 | 536 | 435 | 409 | 445 |
| Expenses | 525 | 478 | 412 | 439 | 508 | 438 | 417 | 444 | 492 | 406 | 374 | 410 | 414 | 386 | 360 | 378 |
| Operating Profit | 143 | 106 | 52 | 34 | 140 | 54 | 47 | 70 | 147 | 56 | 84 | 76 | 122 | 49 | 49 | 67 |
| Other Income | 48 | 50 | 0 | 21 | 36 | 16 | 19 | 35 | 28 | 20 | 25 | 27 | 29 | 7 | 18 | 13 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 15 | 14 | 15 | 15 | 15 | 16 | 13 | 14 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Profit Before Tax | 175 | 140 | 36 | 38 | 160 | 53 | 51 | 90 | 163 | 65 | 98 | 93 | 141 | 45 | 57 | 69 |
| Tax % | 24.0% | 26.0% | 22.0% | 26.0% | 24.0% | 27.0% | 28.0% | 20.0% | 27.0% | 29.0% | 19.0% | 25.0% | 22.0% | 32.0% | 28.0% | 25.0% |
| Net Profit | 132 | 103 | 28 | 28 | 121 | 39 | 37 | 72 | 119 | 46 | 79 | 70 | 110 | 31 | 41 | 52 |
| Exceptional Items | -- | 0 | -21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |
| EPS (Rs) | 8.1 | 6.3 | 1.7 | 1.7 | 7.5 | 2.4 | 2.3 | 4.4 | 7.3 | 2.8 | 4.9 | 4.3 | 6.6 | 1.9 | 2.5 | 3.1 |
| Sales Growth (YoY) | 3.1% | 18.9% | 0.2% | -8.0% | 1.6% | 6.5% | 1.3% | 5.8% | 19.0% | 6.2% | 12.0% | 9.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 14.2% | 25.8% | -1.7% | -27.0% | 31.7% | 6.0% | -9.7% | -19.4% | 38.1% | 0.9% | -5.8% | -9.3% | 23.2% | 6.4% | -8.1% | -- |
| OP Growth (YoY) | 2.1% | 96.3% | 10.6% | -51.4% | -4.8% | -3.6% | -44.0% | -7.9% | 20.5% | 14.3% | 71.4% | 13.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 34.9% | 103.8% | 52.9% | -75.7% | 159.3% | 14.9% | -32.9% | -52.4% | 162.5% | -33.3% | 10.5% | -37.7% | 149.0% | 0.0% | -26.9% | -- |
| Profit Growth (YoY) | -- | 167.0% | 18.0% | -61.0% | 2.0% | -16.0% | -53.0% | 3.0% | 8.0% | 51.0% | 94.0% | 35.0% | 55.0% | 194.0% | 14.2% | -28.0% |
| EPS Growth (YoY) | 9.3% | 166.8% | -23.7% | -60.6% | 1.9% | -16.2% | -53.2% | 3.0% | 10.4% | 53.5% | 98.0% | 37.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 28.2% | 264.9% | 0.0% | -76.6% | 213.0% | 4.4% | -48.4% | -39.5% | 157.4% | -41.7% | 13.5% | -35.2% | 257.8% | -24.8% | -21.1% | -- |
| OP Margin | 21.4% | 18.1% | 11.2% | 7.2% | 21.6% | 11.0% | 10.1% | 13.6% | 23.0% | 12.1% | 18.3% | 15.6% | 22.8% | 11.3% | 12.0% | 15.1% |
| Net Margin | 19.8% | 17.6% | 6.0% | 5.9% | 18.7% | 7.9% | 8.0% | 14.0% | 18.6% | 10.0% | 17.3% | 14.4% | 20.5% | 7.1% | 10.0% | 11.7% |
| Material Cost % | -- | 35.2% | 32.6% | 30.6% | 32.3% | 32.8% | 34.7% | 35.6% | 36.2% | 33.2% | 32.9% | 34.8% | 34.0% | 35.4% | 37.4% | 36.3% |
| Employee Cost % | -- | 18.7% | 25.8% | 25.5% | 20.4% | 24.7% | 25.6% | 24.3% | 18.4% | 22.3% | 22.6% | 20.6% | 19.8% | 22.8% | 23.3% | 22.0% |
| P/S | 2.53 | 3.02 | 3.37 | 2.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 18.95 | 23.30 | 32.27 | 25.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.23 | 2.70 | 2.88 | 2.39 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50FDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve This is to inform you that a meeting of ....
Certificate under Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Newspaper Publication - Corrigendum to 86th AGM Notice- Cut-off date & Book Closure period FY 2025-26.
This is to inform you that a typographical error has occurred in the notice of the 86th AGM for FY 2025-26. The cutoff date for e-voting shall be read as September 17, 2026, instead of ....
Newspaper Publication of the convening of the 86th Annual General Meeting of the Company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandan Mohan Chandavarkar
Please find attached copies of the newspaper advertisement in respect of the 86th AGM of the Company
Please find enclosed Notice of 86th Annual General meeting for the FY 2025-26
Annual Report for FY 2025-26
This is to inform you that the register of members and share transfer books of the Company will remain closed from Thursday, September 17, 2026, to Wednesday, September 23, 2026 (both days ....
BRSR for FY 2025-26
Announcement under Regulation 30
This is to inform you that the company''s Subsidiary, FDC International Ltd., has received Marketing Authorisation from the MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.
Outcome for the Board Meeting Held on 5th August, 2026.
Financial Results for the quarter ended June 30, 2026
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
FDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandhya Mohan Chandavarkar Trust (through its ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandan Mohan Chandavarkar & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mohan Anand Chandavarkar Trust (through its ....
Trading Window of the Company shall remain closed for all the Designated persons, Connected persons and their relative(s) with effect from July 01, 2026, till 48 hours after the declaration ....
This is with regards to our intimation made on May 27, 2026 for Press Release wherein there was typographical error in the Subject line of Press Release in the mentioned year, which shall ....
Please find attached the scrutinizer report for Postal Ballot
Annual Secretarial Compliance report of FDC Limited for Financial year ending March 31, 2026.
Please find attached the outcome of Postal Ballot
Board meeting outcome for approval of the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31, 2026.
Approved Standalone and consolidated financial results for the financial year ending March 31, 2026
Press release on Q4, FY 2026-27 and 12 months, FY 2026-27 results
Announcement under Regulation 30 - ANDA approval
FDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held ....
Newspaper publication - Corrigendum in respect of Postal Ballot Notice dated 21st April, 2026
Information regarding the Notice of the opening of a special window for re-lodgment of the transfer requests of physical shares and for claiming of unclaimed dividend under the " Saksham ....
Corrigendum to Postal Ballot Notice dated April 21, 2026
Copies of Newspaper advertisement regarding the Notice of Postal Ballot.
Confirmation regarding Company not falling under Large Corporate criteria as on March 31, 2026
Intimation of Postal Ballot Notice
This is to inform you that the Board of Directors have approved seeking Shareholder''s approval through Postal Ballot with regard to appointment of Mr. Kishore Saletore as an Independent Director.
Please find attached Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018.
Intimation of Closure of trading window
General update
Please find attached Announcement under Regulation 30( LODR), 2015 Pertaining to Change in Directorate.
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi C Bhanot & Virgo Advisors Pvt Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virgo Advisors Pvt Ltd
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi C Bhanot
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi C Bharot
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015
PFA the Record Date intimation
We hereby inform that the Board meeting held on February 05, 2026 has approved an Interim Dividend of Rs. 5/- per Equity Share of face value of Rs. 1/- each for financial year 2025-26.
Annual Reports
14Concalls
11Nov 2023
30 Nov 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Dec 2021
31 Dec 2021Jun 2017
30 Jun 2017Nov 2016
30 Nov 2016May 2016
31 May 2016Held by ETFs
1 ETFs hold fdc · sorted by weight
Held by Mutual Funds
11 schemes hold fdc · sorted by weight